Medexus PharmaceuticalsMEDXF +3.96%60 Median PS Value is $2.11 as of Jul. 03, 2026, which is 628% above its 10-year median of 0.29. GuruFocus rates MEDXF with a GF Score™ of 60/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 545 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 87.16% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Medexus Pharmaceuticals's Median PS Value or its related term are showing as below:
MEDXF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1 Med: 0.29 Max: 1.74
Current: 1.72
During the past 13 years, the highest Price to Median PS Value of Medexus Pharmaceuticals was 1.74. The lowest was 0.10. And the median was 0.29.
MEDXF's Price-to-Median-PS-Value is ranked worse than 87.16% of 545
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs MEDXF: 1.72
Medexus Pharmaceuticals (OTCPK:MEDXF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Medexus Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.62
/
2.11
=
1.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals Median PS Value Related Terms
Medexus Pharmaceuticals Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.6916.
Medexus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (MEDXF) has a Median PS Value of $2.11 as of Jul. 03, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medexus Pharmaceuticals and its competitors. This is 628% above median its historical median of 0.29. Over the past decade, Medexus Pharmaceuticals' Median PS Value has ranged from 0.10 to 1.74. According to the industry distribution chart, Medexus Pharmaceuticals ranks #475 out of 545 companies in the Drug Manufacturers industry, placing it in the top 87.2%.
Is Medexus Pharmaceuticals' Median PS Value too high?
Medexus Pharmaceuticals' current Median PS Value of $2.11 is 628% above median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.74. The Drug Manufacturers industry median Median PS Value is 0.86. Medexus Pharmaceuticals' value of $2.11 is 145.3% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #475 out of 545 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #475 out of 545 companies for Median PS Value. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median Median PS Value is 0.86. Medexus Pharmaceuticals' value of $2.11 is 145.3% above this benchmark. Historically, Medexus Pharmaceuticals' own Median PS Value has ranged from 0.10 to 1.74 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.86, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Median PS Value of $2.11 is 145.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Median PS Value is $2.11, which is 628% above median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current Median PS Value is $2.11, which is 628% above median its 10-year median of 0.29 and 145.3% above the Drug Manufacturers industry median of 0.86. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Median PS Value is $2.11 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
Median PS Value: $2.11 (628% above median its 10-year median of 0.29)
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
Industry Position: 145.3% above the Drug Manufacturers median (#475 of 545)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score
Get the complete analysis for MEDXF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
